Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71610-743

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71610-743). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 60 mg (71610 0743 30)

Duloxetine Delayed-Release 60 mg capsules label showing a package of 30 capsules. The label includes storage instructions, manufacturer information (GSMs, Inc., Camarillo, CA), and the labeler (Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN). The National Drug Code (NDC) 71610-0743-30 is displayed along with lot and expiration date areas.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, showing the arrangement of its aromatic rings, oxygen, sulfur-containing thiophene ring, methylamine group, and hydrochloride (HCl) component.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the proportion of patients with relapse over time (days) from randomization, comparing placebo (dashed line) and duloxetine delayed-release capsules (solid line). The vertical axis represents the proportion of patients with relapse, and the horizontal axis shows time up to 250 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph showing the proportion of patients with relapse over time (days) from randomization, comparing placebo to Duloxetine delayed-release capsules. The graph indicates patient relapse proportions on the y-axis and time in days on the x-axis, with placebo and Duloxetine treatment curves distinctly marked.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved relative to the percent improvement in pain from baseline. Four lines represent Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, with the percentage of patients improved decreasing as percent pain improvement increases.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and a placebo over varying levels of pain improvement.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph comparing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis among three groups: Duloxetine 60 mg twice daily (DUL 60mg Twice Daily), Duloxetine 60 mg once daily (DUL 60mg Once Daily), and placebo. The graph shows trends of patient response to treatment over increasing pain improvement percentages.*

FDA Label Image

Figure 6 (Duloxetine 07)

Line graph showing percent improvement in pain from baseline plotted against the percent improvement of patients improved. The graph compares four groups: DUL 120 mg once daily, DUL 60 mg once daily, DUL 20 mg once daily, and placebo, with data points decreasing from left to right across the x-axis (percent improvement in pain).*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline, showing data for placebo and Duloxetine delayed-release capsules (60 mg) taken once daily. The graph illustrates relative treatment effects across a range of pain improvement percentages.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) for Duloxetine Delayed-Release 60 mg once daily versus placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved, with data points and trends for both treatment groups.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and Duloxetine Delayed-Release 60 mg/120 mg once daily. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved, with Duloxetine demonstrating higher improvement percentages across most ranges compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.